The University of Kansas Cancer Center Kansas City Vascular Symposium A Case-Based Update for Primary Care 2022

20 $

‘+ Include: 25 videos + 1 pdf, size: 1.38 GB

+ Target Audience: cardiologist, primary care physican

Description

+ Include: 25 videos + 1 pdf, size: 1.38 GB

+ Target Audience: cardiologist, primary care physican

+ Sample video: contact me for sample video

+ Information:

OBJECTIVES

  • Describe advances in medical therapy for vascular disease
  • Utilize innovative technologies and treatments
  • Identify current evidence-based interventions for lower extremity arterial disease in the diabetic foot
  • Discuss current management of neurovascular disease
  • Identify treatment options for venous disease
DISCLOSURE STATEMENTS

Speakers:

Michael Abraham, MD, Adam Alli, MD, Kamal Gupta, MD, Aaron M. Rohr, MD, and Axel Thors, DO, Assistant Professor have no relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

Kamal Gupta, MD has indicated the presentation may include discussion of any off-label uses of a product. Explanation Given: renal denervation and other technologies are not yet approved in the US

Planners and other Administrative Support:

Monya Floyd, BA, Kirk Hance, MD, Nancy Grable, MSN, Kamal Gupta, MD, Axel Thors, DO, Assistant Professor, Cait Mestagh, BA, Angela West, RN, Alan Reeves, MD, Amy Mehaffey, RN, Jenny Cho, MD, Assistant Professor of Vascular Surgery, Kaitlyn Polley, BSN, Elizabeth Hart, RN and Brandon Custer, MD, Assistant Professor, Department of Radiology Residents/Fellows have no relevant financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

Adam Alli, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

  • Sirtex Medical – Speaking – Relationship Has Not Ended
  • Penumbra – Speaking – Relationship Has Not Ended

 

 

+ Topics:

Bronchure.pdf
Session 1 Congenital Vascular Malformations Cosmetic to Life-Threatening.mp4
Session 1 Panel discussion.mp4
Session 1 Spider Veins Now You See Them, Now You Don’t.mp4
Session 1 Swelling of the Legs.Is it from Venous Disease.mp4
Session 1 Varicose Veins Evaluation and Treatment.mp4
Session 1 Venous Ulcer Recognition and Treatment.mp4
Session 2 Early Identification and Triage of the Stroke Patient.mp4
Session 2 Innovative Management in Technology of Stroke.mp4
Session 2 Intracerebral Aneurysms A Primer for the General Practitioner.mp4
Session 2 Pseudotumor Cerebri and Headaches Stenting the Pipes.mp4
Session 3 Fenestrated Endografts Treatment for Complex Abdominal Aortic and Thoracoabdominal Aneurysms.mp4
Session 3 Innovations in the Treatment of Hypertension.mp4
Session 3 Panel discussion.mp4
Session 3 Radiation Exposure for the Primary Care Patient Why This Cannot Be Ignored.mp4
Session 3 Trans Carotid Artery Revascularization (TCAR) Treatment of High-Risk Carotid Occlusive Disease.mp4
Session 4 Complex Soft Tissue Reconstructions of the Lower Extremity.mp4
Session 4 Diabetic Foot Small Vessel Disease Advancements in Vessel Reconstruction.mp4
Session 4 Drug Eluting Balloons and Stents for PAD Are They Safe.mp4
Session 4 No Option Patient with Limb Ischemia Are There Options.mp4
Session 4 Panel discussion.mp4
Session 5 Anticoagulation in Peripheral Artery Disease Is There a Role.mp4
Session 5 Deep Venous Thrombosis How Long to Anticoagulate.mp4
Session 5 Is It Time to Use PCSK9 Inhibitors in PAD.mp4
Session 5 Lipoprotein A in Cardiovascular Disease.mp4
Session 5 Panel discussion.mp4

Reviews

There are no reviews yet.

Be the first to review “The University of Kansas Cancer Center Kansas City Vascular Symposium A Case-Based Update for Primary Care 2022”

Your email address will not be published. Required fields are marked *